These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 30726626)

  • 21. The potential role of valsartan + AHU377 ( LCZ696 ) in the treatment of heart failure.
    Voors AA; Dorhout B; van der Meer P
    Expert Opin Investig Drugs; 2013 Aug; 22(8):1041-7. PubMed ID: 23663006
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In brief: Sacubitril/valsartan (Entresto) expanded indication.
    Med Lett Drugs Ther; 2021 May; 63(1623):65. PubMed ID: 33976096
    [No Abstract]   [Full Text] [Related]  

  • 23. LCZ696 (Valsartan/Sacubitril)--A Possible New Treatment for Hypertension and Heart Failure.
    Andersen MB; Simonsen U; Wehland M; Pietsch J; Grimm D
    Basic Clin Pharmacol Toxicol; 2016 Jan; 118(1):14-22. PubMed ID: 26280447
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared With Valsartan in HFpEF.
    Vaduganathan M; Claggett BL; Desai AS; Anker SD; Perrone SV; Janssens S; Milicic D; Arango JL; Packer M; Shi VC; Lefkowitz MP; McMurray JJV; Solomon SD
    J Am Coll Cardiol; 2020 Jan; 75(3):245-254. PubMed ID: 31726194
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Do Limitations in the Design of PARADIGM-HF Justify the Slow Real World Uptake of Sacubitril/Valsartan (Entresto)?
    Ahn R; Prasad V
    Cardiovasc Drugs Ther; 2018 Dec; 32(6):633-635. PubMed ID: 30232657
    [No Abstract]   [Full Text] [Related]  

  • 26. PROVIDE-HF primary results: Patient-Reported Outcomes inVestigation following Initiation of Drug therapy with Entresto (sacubitril/valsartan) in heart failure.
    Mentz RJ; Xu H; O'Brien EC; Thomas L; Alexy T; Gupta B; Vilaro J; Lala A; DeVore AD; Dhingra R; Briasoulis A; Simon MA; Stehlik J; Rodgers JE; Dunlay SM; Abshire M; Wells QS; Barringhaus KG; Eckman PM; Lowes BD; Espinoza J; Blanco R; Shen X; Duffy CI; Hernandez AF
    Am Heart J; 2020 Dec; 230():35-43. PubMed ID: 32980364
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sacubitril-valsartan: novel therapy for heart failure.
    Sehn E; McDonald T; Lindblad AJ
    Can Fam Physician; 2017 Sep; 63(9):697. PubMed ID: 28904036
    [No Abstract]   [Full Text] [Related]  

  • 28. Sacubitril/valsartan in heart failure with reduced ejection fraction patients: Real world experience on advanced chronic kidney disease, hypotension, and dose escalation.
    Chang HY; Feng AN; Fong MC; Hsueh CW; Lai WT; Huang KC; Chong E; Chen CN; Chang HC; Yin WH
    J Cardiol; 2019 Oct; 74(4):372-380. PubMed ID: 30982680
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Titration and Tolerability of Sacubitril/Valsartan for Patients With Heart Failure in Clinical Practice.
    Du AX; Westerhout CM; McAlister FA; Shanks M; Oudit GY; Paterson DI; Hanninen M; Thomas J; Ezekowitz JA
    J Cardiovasc Pharmacol; 2019 Mar; 73(3):149-154. PubMed ID: 30540684
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial.
    Vardeny O; Claggett B; Packer M; Zile MR; Rouleau J; Swedberg K; Teerlink JR; Desai AS; Lefkowitz M; Shi V; McMurray JJ; Solomon SD;
    Eur J Heart Fail; 2016 Oct; 18(10):1228-1234. PubMed ID: 27283779
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study.
    Wachter R; Senni M; Belohlavek J; Straburzynska-Migaj E; Witte KK; Kobalava Z; Fonseca C; Goncalvesova E; Cavusoglu Y; Fernandez A; Chaaban S; Bøhmer E; Pouleur AC; Mueller C; Tribouilloy C; Lonn E; A L Buraiki J; Gniot J; Mozheiko M; Lelonek M; Noè A; Schwende H; Bao W; Butylin D; Pascual-Figal D;
    Eur J Heart Fail; 2019 Aug; 21(8):998-1007. PubMed ID: 31134724
    [TBL] [Abstract][Full Text] [Related]  

  • 32. What proportion of patients with chronic heart failure are eligible for sacubitril-valsartan?
    Pellicori P; Urbinati A; Shah P; MacNamara A; Kazmi S; Dierckx R; Zhang J; Cleland JGF; Clark AL
    Eur J Heart Fail; 2017 Jun; 19(6):768-778. PubMed ID: 28244205
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF.
    Jhund PS; Fu M; Bayram E; Chen CH; Negrusz-Kawecka M; Rosenthal A; Desai AS; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Solomon SD; Swedberg K; Zile MR; McMurray JJ; Packer M;
    Eur Heart J; 2015 Oct; 36(38):2576-84. PubMed ID: 26231885
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
    Hubers SA; Brown NJ
    Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The safety of sacubitril-valsartan for the treatment of chronic heart failure.
    Tyler JM; Teerlink JR
    Expert Opin Drug Saf; 2017 Feb; 16(2):257-263. PubMed ID: 28060547
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Practical considerations on the introduction of sacubitril/valsartan in clinical practice: Current evidence and early experience.
    Farmakis D; Bistola V; Karavidas A; Parissis J
    Int J Cardiol; 2016 Nov; 223():781-784. PubMed ID: 27573608
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sacubitril/Valsartan-Associated Small Bowel Ileus.
    Hanefeld-Fox L; Jimenez L; Heflin R; Quiel L
    Am J Ther; 2018; 25(6):e705-e706. PubMed ID: 29324464
    [No Abstract]   [Full Text] [Related]  

  • 38. Sacubitril/Valsartan is useful and safe in elderly people with heart failure and reduced ejection fraction. Data from a real-word cohort.
    Esteban-Fernández A; Díez-Villanueva P; Vicent L; Bover R; Gómez-Bueno M; De Juan J; Iniesta ÁM; García-Aguado M; Martínez-Sellés M
    Rev Esp Geriatr Gerontol; 2020; 55(2):65-69. PubMed ID: 31892433
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Life Threatening Angioedema Due to Valsartan/Sacubitril With Previously Well-Tolerated ACE Inhibitor.
    Raheja H; Kumar V; Kamholz S; Hollander G; Shani J
    Am J Ther; 2018; 25(4):e508-e509. PubMed ID: 28452844
    [No Abstract]   [Full Text] [Related]  

  • 40. Rationale and design of TRANSITION: a randomized trial of pre-discharge vs. post-discharge initiation of sacubitril/valsartan.
    Pascual-Figal D; Wachter R; Senni M; Belohlavek J; Noè A; Carr D; Butylin D
    ESC Heart Fail; 2018 Apr; 5(2):327-336. PubMed ID: 29239515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.